{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-006382","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.913407+00:00","generated_at":"2026-06-18T05:05:52.174380+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Perspective Therapeutics terminates Chief R&D Officer Cavanagh; separation payment of $341,000","bullets":["William Cavanagh III departed as Chief R&D Officer effective Feb 7, 2023; Separation Agreement effective Mar 10, 2023.","Cavanagh receives $341,000 (12 months base salary) paid biweekly, plus health premium equivalent for one year.","Separation includes full release of claims against the company and confidentiality/non-disparagement obligations.","Stock options: unvested options terminate; vested options expire 90 days from Feb 7, 2023.","Agreement includes 45-day consideration period and 7-day revocation period under ADEA."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-006382","json":"https://secwatch.observer/filing/0001437749-23-006382.json","markdown":"https://secwatch.observer/filing/0001437749-23-006382.md","text":"https://secwatch.observer/filing/0001437749-23-006382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/0001437749-23-006382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/isr20230309_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:05:52.174380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c1bcec2757","claim":"William Cavanagh III was terminated as Chief Research and Development Officer at Perspective Therapeutics, Inc..","evidence_excerpt":"In connection with the termination of William Cavanagh III from his position of Chief Research and Development Officer of Perspective Therapeutics, Inc. (the “ Company ”), as previously disclosed on the Form 8-K filed by the Company on February 10, 2023, the Company, Isoray Medical, Inc. (a wholly-owned subsidiary of the Company), and Mr. Cavanagh entered into a Separation Agreement effective March 10, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923006382/0001437749-23-006382-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Research and Development Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}